UCI said it received a $6 million grant from the California Institute for Regenerative Medicine to perform preclinical trial studies on jaw joint implant Hyaleon. Hyaleon, the main product of UCI-based startup Cartilage Inc., aims to treat adults living with a temporomandibular joint (TMJ) disorder. According to officials, about one in four adults suffer from a TMJ pathology, and up to 70% of cases involve displacement of the TMJ disk. “Total joint replacement is performed for end-stage cases, but this is considered to be a drastic step,” Kyriacos Athanasiou, a biomedical engineering researcher at UCI who led the development of Hyaleon, said in a statement. [Subscription required, you can request an electronic copy of the article by sending an email to communications@uci.edu.] Read More